Epithalon + Follistatin Stack

Epithalon (designation AEDG, reflecting its amino acid sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled on Epithalamin, a bovine pineal gland extract. Its best-characterized proposed mechanism is activation of telomerase, the ribonucleoprotein enzyme that synthesizes the TTAGGG repeat sequences at chromosome termini. A 2003 in vitro study demonstrated that Epithalon induced expression of the catalytic telomerase subunit (hTERT) and measurably elongated telomeres in human fetal fibroblasts that ordinarily lack telomerase activity. Separately, Epithalon has been shown to cause decondensation of pericentromeric heterochromatin in cultured lymphocytes from donors aged 76–80, potentially releasing genes repressed by age-related chromatin compaction. The peptide also stimulates melatonin synthesis in pineal cells and modulates expression of circadian clock genes including Cry2 and Csnk1e, effects demonstrated in both primate models and a small human trial.

Follistatin-344 is the 344-amino acid isoform of follistatin, a naturally occurring glycoprotein that sequesters members of the TGF-beta superfamily, most potently myostatin (GDF-8) and activin A. Crystallographic and biochemical studies confirm that two follistatin molecules wrap around the myostatin or activin dimer, burying their receptor-binding surfaces. This prevents engagement of the type IIA and IIB activin receptors (ActRIIA and ActRIIB), blocking downstream Smad2 and Smad3 phosphorylation. Because phosphorylated Smad2/3 would otherwise translocate to the nucleus and transcriptionally suppress muscle protein synthesis, follistatin-mediated sequestration results in disinhibition of myogenesis and satellite cell recruitment, enabling skeletal muscle hypertrophy.

For Epithalon, the published evidence base comes predominantly from one research group at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. Independent replication is sparse, which is a significant limitation. The 2003 cell-culture study (PMID 12937682) demonstrated telomerase induction and telomere elongation in human fibroblasts but involved no human subjects. A mouse longevity experiment published in Biogerontology (DOI 10.1023/A:1025114230714) reported a 13.3% increase in maximum lifespan among the last 10% of surviving female SHR mice treated with Epitalon, along with reduced spontaneous mammary tumor incidence, but this has not been independently replicated. A non-randomized primate study (PMID 11524632) showed normalization of melatonin and cortisol circadian rhythms in senescent rhesus macaques following Epithalon administration. In humans, a study of 162 retinitis pigmentosa patients receiving 5 mcg parabulbar injections reported visual acuity improvements in roughly 64.8% of subjects. A separate report in 75 women receiving 0.5 mg per day sublingual Epithalon for 20 days found a 1.6-fold increase in melatonin metabolites and significant modulation of circadian clock gene expression. A 2025 systematic review in the International Journal of Molecular Sciences (PMC11943447) concluded that the complete mechanism of action remains unclear and that critical safety data are absent.

For Follistatin, the only published human interventional evidence comes from a Phase 1/2a gene therapy trial (PMID 25322757) in which AAV1.CMV.FS344 was injected bilaterally into the quadriceps of 6 ambulatory Becker muscular dystrophy patients. Four of the six showed improvements in the 6-minute walk test ranging from 29 to 125 meters over roughly one year, with histological evidence of reduced fibrosis and more normal fiber size distribution. No serious adverse events related to the vector were reported. This trial used viral gene delivery, not subcutaneously injected peptide, and results cannot be directly extrapolated to exogenous Follistatin-344 administration. Animal models consistently show 15–50% increases in lean muscle mass with follistatin overexpression, with larger effects when combined with mechanical loading.

No published clinical study has evaluated the Epithalon plus Follistatin-344 combination as a co-administered stack.

Typical dosage: Protocol varies (cycled).

Neither Epithalon nor Follistatin-344 is approved by any regulatory agency, and no consensus clinical dosing guidelines exist for either compound. The following reflects dosing reported in the peer-reviewed literature and in research-use community practice.

Epithalon in published human studies has been administered at 0.5 mg per day sublingually for 20 consecutive days in the circadian gene trial, and at 5 mcg per eye as parabulbar injection in the retinitis pigmentosa study. In animal studies, doses of 0.1–1 mcg per mouse were used. The community convention, which is not derived from published human pharmacokinetic or dose-finding studies, calls for cycles of 5–10 mg per day by subcutaneous injection for 10–20 consecutive days, repeated 1–3 times per year. Some practitioners report using an intranasal or sublingual route to avoid injection.

• Subcutaneous cycle (community): 5–10 mg per day for 10–20 days, 1–3 cycles per year • Sublingual (human study): 0.5 mg per day for 20 days

Follistatin-344 injectable peptide has no validated clinical dosing basis. Community and research forums describe doses of 50–200 mcg per day administered subcutaneously, typically in cycles of 10–30 days with equivalent off-periods. Most protocols suggest starting conservatively at 50–100 mcg per day and limiting cycle length due to theoretical risks. The Phase 1/2a gene therapy trial used 3–6 x 10^11 vector genome copies per kilogram per leg; this figure is not applicable to peptide injection.

• Injectable peptide (community): 50–200 mcg per day subcutaneously for 10–30 days

This information is provided solely for educational and encyclopedic reference purposes and does not constitute medical advice. Neither compound is approved for human therapeutic use by the FDA or equivalent regulatory bodies, and self-administration carries unquantified risks.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The pairing of Epithalon with Follistatin-344 is reported in performance and anti-aging communities as targeting two complementary biological axes: Epithalon for cellular longevity, telomere maintenance, and circadian neuroendocrine restoration; Follistatin-344 for myostatin inhibition and skeletal muscle preservation. The underlying rationale is that aging-associated muscle loss (sarcopenia) coincides with both declining telomere integrity and elevated myostatin activity, making dual targeting mechanistically plausible. No published preclinical or clinical study has evaluated this specific combination, and all claims about synergistic or additive effects are entirely anecdotal.

Within anti-aging practice, Epithalon is also reported — at the anecdotal level — to be stacked with GHK-Cu (a copper-binding tripeptide with proposed antioxidant and wound-healing properties), with NAD+ precursors for mitochondrial support, and with growth-hormone-releasing peptide combinations such as CJC-1295 plus Ipamorelin for body-composition goals. These combinations share no controlled clinical evidence. Practitioners cite the absence of known mechanistic conflicts between the agents, but pharmacodynamic interactions have not been studied.

Epithalon + Follistatin Stack is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed Epithalon + Follistatin Stack from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place Epithalon + Follistatin Stack on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Monitor individually

Epithalon: the published literature reports no serious adverse events at study doses. The most commonly noted effects in clinical use are mild and transient injection-site reactions (redness, minor swelling), occasional headache, and vivid dreams attributed to melatonin normalization. The 2025 IJMS review (PMC11943447) explicitly cautioned that critical safety information remains incomplete and that no adequate toxicology studies have been performed to support approval as a pharmaceutical ingredient. The FDA has listed Epithalon among peptides raising immunogenicity concerns. The most significant theoretical concern is that telomerase reactivation, the proposed primary mechanism, could potentially accelerate proliferation in pre-malignant cells; published studies have not demonstrated this, but available studies are too short-term and small to exclude the risk. Epithalon is not approved for human use.

Follistatin-344: Because follistatin sequesters activin alongside myostatin, it disrupts the activin-FSH hormonal axis and may impair reproductive hormone regulation; this effect is documented in animal models and is a plausible concern in humans. Rapid skeletal muscle hypertrophy without proportional tendon and ligament adaptation introduces a structural injury risk, including tendinopathy and ligament tears. A theoretical concern exists that broad inhibition of TGF-beta family signaling could remove normal growth restraints on pre-existing neoplastic tissue; this has not been observed in published human studies but has not been adequately evaluated. The Phase 1/2a gene therapy trial (n=6) observed no serious treatment-related adverse events, but the injectable peptide route has no comparable safety record in humans. Long-term safety data are absent for both compounds. Follistatin-344 is not approved for human use.

Specific contraindications for either compound have not been formally established in clinical trials. Use in individuals with a history of cancer, reproductive disorders, or autoimmune conditions warrants particular caution given the proposed mechanisms.